Tuesday , November 21 2017
Home / Resources / Videos / ADA 2017 / Samuel Engel Part 4, Diabetes Therapies That Don’t Cause Hypoglycemia

Samuel Engel Part 4, Diabetes Therapies That Don’t Cause Hypoglycemia

In part 4 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about looking at the impact of DPP-4s on hypoglycemia.

Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories.

Transcript of this video segment:

Steve Freed: In one of the other studies that reduces burden of hypoglycemia related to DPP-4 inhibitor use, that was an abstract. Was that an oral also?

Samuel Engel: That was a study done by our colleagues at the Merck Center for Observational and Real World Evidence, and there was an analysis that was done looking over the course of the last number of years when DPP-4 inhibitors were available, the rates of hypoglycemia that were seen in patients taking DPP-4 inhibitors compared to patients taking sulfonylureas. What the authors did was they then projected if DPP-4 inhibitors hadn’t been available, what levels of hypoglycemia would have occurred and what would have been the patient burden as well as the cost burden? And it showed about 50% of the hypoglycemia that would have happened in the absence of DPP-4 inhibitors actually didn’t because of the availability of that class.

Steve Freed: What would you like the physicians to walk away from and with what understanding?

Samuel Engel: I think it highlights the importance of therapies for diabetes that don’t cause hypoglycemia. Hypoglycemia is a burden to patients in terms of their daily life, a burden in terms of the economic cost to healthcare system; it’s a burden in regards to the potential relationship of hypoglycemia, especially severe hypoglycemia with more substantial health issues. Even been linked with increased mortality. In that context, studies that continue to highlight the difference in hypoglycemia rates for DPP-4 inhibitors, and this would also hold for SGLT-2 inhibitors, provide the evidence base that clinicians and patients need now that there are so many different choices and classes of anti-hyperglycemic drugs.

Steve Freed: I want to thank you for your time, I found that to be very interesting, and enjoy the rest of your stay here.

Samuel Engel: Thank you very much.

Return to the main page.